Cargando…

COVID-19 in patients with lung cancer

BACKGROUND: Patients with lung cancers may have disproportionately severe coronavirus disease 2019 (COVID-19) outcomes. Understanding the patient-specific and cancer-specific features that impact the severity of COVID-19 may inform optimal cancer care during this pandemic. PATIENTS AND METHODS: We e...

Descripción completa

Detalles Bibliográficos
Autores principales: Luo, J., Rizvi, H., Preeshagul, I.R., Egger, J.V., Hoyos, D., Bandlamudi, C., McCarthy, C.G., Falcon, C.J., Schoenfeld, A.J., Arbour, K.C., Chaft, J.E., Daly, R.M., Drilon, A., Eng, J., Iqbal, A., Lai, W.V., Li, B.T., Lito, P., Namakydoust, A., Ng, K., Offin, M., Paik, P.K., Riely, G.J., Rudin, C.M., Yu, H.A., Zauderer, M.G., Donoghue, M.T.A., Łuksza, M., Greenbaum, B.D., Kris, M.G., Hellmann, M.D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: European Society for Medical Oncology. Published by Elsevier Ltd. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7297689/
https://www.ncbi.nlm.nih.gov/pubmed/32561401
http://dx.doi.org/10.1016/j.annonc.2020.06.007
_version_ 1783547057462575104
author Luo, J.
Rizvi, H.
Preeshagul, I.R.
Egger, J.V.
Hoyos, D.
Bandlamudi, C.
McCarthy, C.G.
Falcon, C.J.
Schoenfeld, A.J.
Arbour, K.C.
Chaft, J.E.
Daly, R.M.
Drilon, A.
Eng, J.
Iqbal, A.
Lai, W.V.
Li, B.T.
Lito, P.
Namakydoust, A.
Ng, K.
Offin, M.
Paik, P.K.
Riely, G.J.
Rudin, C.M.
Yu, H.A.
Zauderer, M.G.
Donoghue, M.T.A.
Łuksza, M.
Greenbaum, B.D.
Kris, M.G.
Hellmann, M.D.
author_facet Luo, J.
Rizvi, H.
Preeshagul, I.R.
Egger, J.V.
Hoyos, D.
Bandlamudi, C.
McCarthy, C.G.
Falcon, C.J.
Schoenfeld, A.J.
Arbour, K.C.
Chaft, J.E.
Daly, R.M.
Drilon, A.
Eng, J.
Iqbal, A.
Lai, W.V.
Li, B.T.
Lito, P.
Namakydoust, A.
Ng, K.
Offin, M.
Paik, P.K.
Riely, G.J.
Rudin, C.M.
Yu, H.A.
Zauderer, M.G.
Donoghue, M.T.A.
Łuksza, M.
Greenbaum, B.D.
Kris, M.G.
Hellmann, M.D.
author_sort Luo, J.
collection PubMed
description BACKGROUND: Patients with lung cancers may have disproportionately severe coronavirus disease 2019 (COVID-19) outcomes. Understanding the patient-specific and cancer-specific features that impact the severity of COVID-19 may inform optimal cancer care during this pandemic. PATIENTS AND METHODS: We examined consecutive patients with lung cancer and confirmed diagnosis of COVID-19 (n = 102) at a single center from 12 March 2020 to 6 May 2020. Thresholds of severity were defined a priori as hospitalization, intensive care unit/intubation/do not intubate ([ICU/intubation/DNI] a composite metric of severe disease), or death. Recovery was defined as >14 days from COVID-19 test and >3 days since symptom resolution. Human leukocyte antigen (HLA) alleles were inferred from MSK-IMPACT (n = 46) and compared with controls with lung cancer and no known non-COVID-19 (n = 5166). RESULTS: COVID-19 was severe in patients with lung cancer (62% hospitalized, 25% died). Although severe, COVID-19 accounted for a minority of overall lung cancer deaths during the pandemic (11% overall). Determinants of COVID-19 severity were largely patient-specific features, including smoking status and chronic obstructive pulmonary disease [odds ratio for severe COVID-19 2.9, 95% confidence interval 1.07–9.44 comparing the median (23.5 pack-years) to never-smoker and 3.87, 95% confidence interval 1.35–9.68, respectively]. Cancer-specific features, including prior thoracic surgery/radiation and recent systemic therapies did not impact severity. Human leukocyte antigen supertypes were generally similar in mild or severe cases of COVID-19 compared with non-COVID-19 controls. Most patients recovered from COVID-19, including 25% patients initially requiring intubation. Among hospitalized patients, hydroxychloroquine did not improve COVID-19 outcomes. CONCLUSION: COVID-19 is associated with high burden of severity in patients with lung cancer. Patient-specific features, rather than cancer-specific features or treatments, are the greatest determinants of severity.
format Online
Article
Text
id pubmed-7297689
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher European Society for Medical Oncology. Published by Elsevier Ltd.
record_format MEDLINE/PubMed
spelling pubmed-72976892020-06-17 COVID-19 in patients with lung cancer Luo, J. Rizvi, H. Preeshagul, I.R. Egger, J.V. Hoyos, D. Bandlamudi, C. McCarthy, C.G. Falcon, C.J. Schoenfeld, A.J. Arbour, K.C. Chaft, J.E. Daly, R.M. Drilon, A. Eng, J. Iqbal, A. Lai, W.V. Li, B.T. Lito, P. Namakydoust, A. Ng, K. Offin, M. Paik, P.K. Riely, G.J. Rudin, C.M. Yu, H.A. Zauderer, M.G. Donoghue, M.T.A. Łuksza, M. Greenbaum, B.D. Kris, M.G. Hellmann, M.D. Ann Oncol Original Article BACKGROUND: Patients with lung cancers may have disproportionately severe coronavirus disease 2019 (COVID-19) outcomes. Understanding the patient-specific and cancer-specific features that impact the severity of COVID-19 may inform optimal cancer care during this pandemic. PATIENTS AND METHODS: We examined consecutive patients with lung cancer and confirmed diagnosis of COVID-19 (n = 102) at a single center from 12 March 2020 to 6 May 2020. Thresholds of severity were defined a priori as hospitalization, intensive care unit/intubation/do not intubate ([ICU/intubation/DNI] a composite metric of severe disease), or death. Recovery was defined as >14 days from COVID-19 test and >3 days since symptom resolution. Human leukocyte antigen (HLA) alleles were inferred from MSK-IMPACT (n = 46) and compared with controls with lung cancer and no known non-COVID-19 (n = 5166). RESULTS: COVID-19 was severe in patients with lung cancer (62% hospitalized, 25% died). Although severe, COVID-19 accounted for a minority of overall lung cancer deaths during the pandemic (11% overall). Determinants of COVID-19 severity were largely patient-specific features, including smoking status and chronic obstructive pulmonary disease [odds ratio for severe COVID-19 2.9, 95% confidence interval 1.07–9.44 comparing the median (23.5 pack-years) to never-smoker and 3.87, 95% confidence interval 1.35–9.68, respectively]. Cancer-specific features, including prior thoracic surgery/radiation and recent systemic therapies did not impact severity. Human leukocyte antigen supertypes were generally similar in mild or severe cases of COVID-19 compared with non-COVID-19 controls. Most patients recovered from COVID-19, including 25% patients initially requiring intubation. Among hospitalized patients, hydroxychloroquine did not improve COVID-19 outcomes. CONCLUSION: COVID-19 is associated with high burden of severity in patients with lung cancer. Patient-specific features, rather than cancer-specific features or treatments, are the greatest determinants of severity. European Society for Medical Oncology. Published by Elsevier Ltd. 2020-10 2020-06-17 /pmc/articles/PMC7297689/ /pubmed/32561401 http://dx.doi.org/10.1016/j.annonc.2020.06.007 Text en © 2020 European Society for Medical Oncology. Published by Elsevier Ltd. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Original Article
Luo, J.
Rizvi, H.
Preeshagul, I.R.
Egger, J.V.
Hoyos, D.
Bandlamudi, C.
McCarthy, C.G.
Falcon, C.J.
Schoenfeld, A.J.
Arbour, K.C.
Chaft, J.E.
Daly, R.M.
Drilon, A.
Eng, J.
Iqbal, A.
Lai, W.V.
Li, B.T.
Lito, P.
Namakydoust, A.
Ng, K.
Offin, M.
Paik, P.K.
Riely, G.J.
Rudin, C.M.
Yu, H.A.
Zauderer, M.G.
Donoghue, M.T.A.
Łuksza, M.
Greenbaum, B.D.
Kris, M.G.
Hellmann, M.D.
COVID-19 in patients with lung cancer
title COVID-19 in patients with lung cancer
title_full COVID-19 in patients with lung cancer
title_fullStr COVID-19 in patients with lung cancer
title_full_unstemmed COVID-19 in patients with lung cancer
title_short COVID-19 in patients with lung cancer
title_sort covid-19 in patients with lung cancer
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7297689/
https://www.ncbi.nlm.nih.gov/pubmed/32561401
http://dx.doi.org/10.1016/j.annonc.2020.06.007
work_keys_str_mv AT luoj covid19inpatientswithlungcancer
AT rizvih covid19inpatientswithlungcancer
AT preeshagulir covid19inpatientswithlungcancer
AT eggerjv covid19inpatientswithlungcancer
AT hoyosd covid19inpatientswithlungcancer
AT bandlamudic covid19inpatientswithlungcancer
AT mccarthycg covid19inpatientswithlungcancer
AT falconcj covid19inpatientswithlungcancer
AT schoenfeldaj covid19inpatientswithlungcancer
AT arbourkc covid19inpatientswithlungcancer
AT chaftje covid19inpatientswithlungcancer
AT dalyrm covid19inpatientswithlungcancer
AT drilona covid19inpatientswithlungcancer
AT engj covid19inpatientswithlungcancer
AT iqbala covid19inpatientswithlungcancer
AT laiwv covid19inpatientswithlungcancer
AT libt covid19inpatientswithlungcancer
AT litop covid19inpatientswithlungcancer
AT namakydousta covid19inpatientswithlungcancer
AT ngk covid19inpatientswithlungcancer
AT offinm covid19inpatientswithlungcancer
AT paikpk covid19inpatientswithlungcancer
AT rielygj covid19inpatientswithlungcancer
AT rudincm covid19inpatientswithlungcancer
AT yuha covid19inpatientswithlungcancer
AT zauderermg covid19inpatientswithlungcancer
AT donoghuemta covid19inpatientswithlungcancer
AT łukszam covid19inpatientswithlungcancer
AT greenbaumbd covid19inpatientswithlungcancer
AT krismg covid19inpatientswithlungcancer
AT hellmannmd covid19inpatientswithlungcancer